Novartis delivered growth across all divisions in second quarter
- Details
- Category: Novartis
Group net sales increased 1% (+3% cc) to USD 14.5 billion in the second quarter, with all divisions contributing to growth in constant currencies. Currency had a negative impact of 2 percentage points mainly from the weakening yen. Excluding the impact of patent expiries, underlying sales grew 8% in constant currencies.
Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
- Details
- Category: Boehringer Ingelheim
Published in the European Journal of Heart Failure1, results from a new sub-analysis of the RE-LY®* trial demonstrate important benefits of Pradaxa® (dabigatran etexilate) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation (AF) and previous symptomatic heart failure (HF).
GSK announces US submission for dabrafenib/trametinib combination in metastatic melanoma
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) plc has announced submission of supplemental New Drug Applications (NDAs) to the US Food and Drug Administration for use of dabrafenib, a BRAF inhibitor, in combination with trametinib, a MEK inhibitor. Supplemental applications were submitted to each of the currently approved NDAs for the use of each drug in combination with the other, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation.
Roche halts investigation of aleglitazar
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that following the results of a regular safety review of the aleglitazar AleCardio phase III trial, the independent Data and Safety Monitoring Board (DSMB) has recommended to halt the trial due to safety signals and lack of efficacy. Based on this recommendation, Roche has decided to terminate the AleCardio trial and all other trials involving aleglitazar.
AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer Research UK for a two-year collaboration on three pre-clinical and clinical oncology projects. This agreement with world-leading medical research institutions based in Cambridge, UK, aims to advance cancer research through the study of tumour mutations and new investigational therapies in prostate, pancreatic and potentially other cancers.
Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world
- Details
- Category: Novartis
Novartis today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths
- Details
- Category: GlaxoSmithKline
GSK and Save the Children have launched a $1 million Healthcare Innovation Award to identify and reward innovations in healthcare which have proven successful in reducing child deaths in developing countries. From the 27th June - 26th August, organisations from across the developing world can nominate examples of innovative healthcare approaches they have discovered or implemented.
More Pharma News ...
- Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials
- AstraZeneca selects location for new global R&D centre and corporate headquarters
- MedImmune, AstraZeneca's biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity
- FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone
- Bristol-Myers Squibb and Simcere enter partnership to co-develop and co-commercialize Orencia® SC (abatacept) in China
- Pfizer obtains $2.15 billion settlement from Teva and Sun for infringement of Protonix® patent
- New four-strain influenza vaccine from Sanofi Pasteur now licensed by FDA